Bimagrumab: Mechanism, Trials, and What the Data Actually Shows
Bimagrumab is a Phase 2b program from Eli Lilly/Versanis built around ActRII antagonist. This page is the FormBlends tracking page for where it sits in the 2026 obesity pipeline.
Developer
Eli Lilly/Versanis
Mechanism
ActRII antagonist
Stage
Phase 2b
Tracked in
Non-incretin mechanisms
Approval and timeline
Need the straight approval read on Bimagrumab?
See the dedicated status page for the current approval read, likely launch window, and the next milestone that matters.
View Bimagrumab statusMechanism tracker
Non-incretin mechanisms
See the broader pipeline lane this compound belongs to and what else matters in it.
Company tracker
Eli Lilly/Versanis
See how this compound fits into the wider company pipeline and what else the sponsor is building.
Compound facts for search and AI answers
What this Bimagrumab tracking page answers
Compound
Bimagrumab from Eli Lilly/Versanis
Bimagrumab is tracked in the non-incretin mechanisms group.
Mechanism
ActRII antagonist
Mechanism explains why this compound belongs in its pipeline bucket.
Current stage
Phase 2b
This program has moved into the middle part of development, where weight-loss signal, dose range, and tolerability start becoming clearer. Phase 2 data can move sentiment fast, but it is still common for programs to stall before registrational trials.
Evidence read
No mature public weight-loss signal pinned yet
Bimagrumab should be read as an evidence-tracking page, not as a patient access page. FormBlends has not pinned this page to a mature public weight-loss signal yet, so mechanism and development stage carry more weight than outcome claims. This program has moved into the middle part of development, where weight-loss signal, dose range, and tolerability start becoming clearer. Phase 2 data can move sentiment fast, but it is still common for programs to stall before registrational trials. The next useful milestone is a clean human readout, regulatory update, or sponsor disclosure that changes the evidence base. This is still a trial-stage compound. It should be treated as a tracking page, not a buying guide. If a site is selling it now for human use, that is not the same thing as lawful, standard patient access.
Clinical evidence snapshot
What the evidence can and cannot say about Bimagrumab
Bimagrumab should be read as an evidence-tracking page, not as a patient access page. FormBlends has not pinned this page to a mature public weight-loss signal yet, so mechanism and development stage carry more weight than outcome claims. This program has moved into the middle part of development, where weight-loss signal, dose range, and tolerability start becoming clearer. Phase 2 data can move sentiment fast, but it is still common for programs to stall before registrational trials. The next useful milestone is a clean human readout, regulatory update, or sponsor disclosure that changes the evidence base. This is still a trial-stage compound. It should be treated as a tracking page, not a buying guide. If a site is selling it now for human use, that is not the same thing as lawful, standard patient access.
Decision path
Is Bimagrumab available now or watchlist only?
Bimagrumab should be interpreted through its current development stage, not through gray-market availability claims. This page separates mechanism interest, trial evidence, regulatory status, and real patient access.
- Compound
- Bimagrumab
- Developer
- Eli Lilly/Versanis
- Stage
- Phase 2b
- Mechanism
- Non-incretin mechanisms
Step 1
Read the stage first
This program has moved into the middle part of development, where weight-loss signal, dose range, and tolerability start becoming clearer. Phase 2 data can move sentiment fast, but it is still common for programs to stall before registrational trials.
Check statusStep 2
Separate evidence from access
This is still a trial-stage compound. It should be treated as a tracking page, not a buying guide. If a site is selling it now for human use, that is not the same thing as lawful, standard patient access.
Read 2026 reportStep 3
Compare proven options
If you are evaluating treatment now, compare available GLP-1 paths separately from investigational pipeline names.
View current optionsFast answers
What is Bimagrumab?
Bimagrumab is a phase 2b obesity or metabolic program from Eli Lilly/Versanis built around ActRII antagonist.
Is Bimagrumab approved?
No. Bimagrumab is still a Phase 2b asset. Its value is not about near-term approval. It is about whether muscle-preservation biology becomes important enough to change the obesity category.
When could it matter?
2028 or later if the adjunct or composition story becomes commercially persuasive.
What Bimagrumab is
Bimagrumab is part of the non-incretin mechanisms cluster in the FormBlends obesity-pipeline map. We track it because Eli Lilly/Versanis is using ActRII antagonist as a bet on what comes after the first wave of blockbuster GLP-1 therapies.
Where it sits in the 2026 pipeline
This program has moved into the middle part of development, where weight-loss signal, dose range, and tolerability start becoming clearer. Phase 2 data can move sentiment fast, but it is still common for programs to stall before registrational trials.
Non-incretin obesity programs matter because they are not just trying to be another GLP-1. They represent alternative bets on muscle preservation, central appetite signaling, energy expenditure, and rare-disease pathways that could reshape the category if they work.
What FormBlends is watching next
For Bimagrumab, the next useful signal is not just another headline. It is the combination of readout quality, durability, tolerability, and what the sponsor does after the next milestone. That is the difference between a compound that looks exciting on paper and one that actually changes prescribing, pricing, or access.
Access and regulatory reality
This is still a trial-stage compound. It should be treated as a tracking page, not a buying guide. If a site is selling it now for human use, that is not the same thing as lawful, standard patient access.
More non-incretin mechanisms on FormBlends
Frequently asked questions
What is Bimagrumab?
Bimagrumab is a Phase 2b obesity or metabolic compound from Eli Lilly/Versanis. FormBlends tracks it in the non-incretin mechanisms group and follows it for trial progress, regulatory movement, and competitive impact.
How does Bimagrumab work?
Bimagrumab is being tracked as a ActRII antagonist program. That mechanism is the main reason it sits inside the non-incretin mechanisms bucket of the 2026 obesity pipeline.
Is Bimagrumab available now?
This is still a trial-stage compound. It should be treated as a tracking page, not a buying guide. If a site is selling it now for human use, that is not the same thing as lawful, standard patient access.
Why is FormBlends tracking Bimagrumab?
Non-incretin obesity programs matter because they are not just trying to be another GLP-1. They represent alternative bets on muscle preservation, central appetite signaling, energy expenditure, and rare-disease pathways that could reshape the category if they work.